Literature DB >> 2449866

3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase.

M H St Clair1, C A Richards, T Spector, K J Weinhold, W H Miller, A J Langlois, P A Furman.   

Abstract

Reverse transcriptase was purified from human immunodeficiency virus (HIV). It utilized the artificial primer-template poly(rA)-oligo(dT)12-18 more efficiently than activated calf thymus DNA, poly(rI)-oligo(dC)12-18, poly(rC)-oligo(dG)12-18, or poly(rCm)-oligo(dG)12-18. Maximum activity was observed at pH 7.0 to 7.6 in the presence of 5 mM MgCl2 and 100 mM KCl. 3'-Azido-3'-deoxythymidine triphosphate competed with dTTP for binding to HIV reverse transcriptase. Different kinetic constants were obtained with different primer-templates. Km and Ki values of 2.8 and 0.04 microM, respectively, were obtained with poly(rA)-oligo(dT)12-18. The corresponding values were 1.2 and 0.3 microM, respectively, with activated calf thymus DNA and 0.3 and 0.01 microM, respectively, with extracted virus and native template. Inhibition of the host cell DNA polymerases alpha and beta was considerably weaker. The Km and Ki values obtained with activated calf thymus DNA as the primer-template were 2.4 and 230 microM, respectively, for DNA polymerase alpha and 6.0 and 73 microM, respectively, for DNA polymerase beta. 3'-Azido-3'-deoxythymidine triphosphate could also serve as an alternate substrate for HIV reverse transcriptase. The resulting incorporation of 3'-azido-3'-deoxythymidine triphosphate into poly(rA)-oligo(dT)12-18 caused chain termination and premature deceleration of the reaction. The terminated primer could not be elongated when incubated with dTTP and HIV reverse transcriptase.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2449866      PMCID: PMC175837          DOI: 10.1128/AAC.31.12.1972

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Statistical estimations in enzyme kinetics.

Authors:  G N WILKINSON
Journal:  Biochem J       Date:  1961-08       Impact factor: 3.857

2.  Inhibition of the reverse transcriptase from HIV by 3'-azido-3'-deoxythymidine triphosphate and its threo analogue.

Authors:  L Vrang; H Bazin; G Remaud; J Chattopadhyaya; B Oberg
Journal:  Antiviral Res       Date:  1987-03       Impact factor: 5.970

Review 3.  RNA-directed DNA synthesis and RNA tumor viruses.

Authors:  H M Temin; D Baltimore
Journal:  Adv Virus Res       Date:  1972       Impact factor: 9.937

4.  Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U).

Authors:  L P Elwell; R Ferone; G A Freeman; J A Fyfe; J A Hill; P H Ray; C A Richards; S C Singer; V B Knick; J L Rideout
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

5.  Statistical methods to distinguish competitive, noncompetitive, and uncompetitive enzyme inhibitors.

Authors:  T Spector; G Hajian
Journal:  Anal Biochem       Date:  1981-08       Impact factor: 3.365

6.  Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase.

Authors:  P A Furman; M H St Clair; T Spector
Journal:  J Biol Chem       Date:  1984-08-10       Impact factor: 5.157

7.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  68 in total

1.  Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease.

Authors:  H Jacobsen; L Ahlborn-Laake; R Gugel; J Mous
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Authors:  R Koshida; L Vrang; G Gilljam; J Harmenberg; B Oberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 3.  Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery.

Authors:  Si'Ana A Coggins; Bijan Mahboubi; Raymond F Schinazi; Baek Kim
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

4.  U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.

Authors:  T J Dueweke; S M Poppe; D L Romero; S M Swaney; A G So; K M Downey; I W Althaus; F Reusser; M Busso; L Resnick
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

5.  Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine.

Authors:  J L Martin; J E Wilson; R L Haynes; P A Furman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

Review 6.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

7.  A photolabile 2',3'-dideoxyuridylate analog bearing an aryl(trifluoromethyl)diazirine moiety: photoaffinity labeling of HIV-1 reverse transcriptase.

Authors:  T Yamaguchi; M Saneyoshi
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

8.  Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.

Authors:  Z Gu; X Li; Y Quan; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

Review 9.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

10.  4'-Acylated thymidine 5'-triphosphates: a tool to increase selectivity towards HIV-1 reverse transcriptase.

Authors:  A Marx; M Amacker; M Stucki; U Hübscher; T A Bickle; B Giese
Journal:  Nucleic Acids Res       Date:  1998-09-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.